Exelixis and Arcus Biosciences Announce Clinical Trial Collaboration to Evaluate Zanzalintinib in Combination with AB521 in Patients with Advanced Renal Cell Carcinoma

ALAMEDA, Calif. & HAYWARD, Calif.–(BUSINESS WIRE)–Exelixis, Inc. (Nasdaq: EXEL) and Arcus Biosciences (NYSE: RCUS) today announced that the companies have entered into a clinical trial collaboration for STELLAR-009, a phase 1b/2 trial evaluating zanzalintinib, Exelixis’ next-generation tyrosine kinase inhibitor (TKI), in combination with AB521, an inhibitor of the transcription factor…
Click here to view original post

Advertisement — Advertise with Biotech Networks